Why Does CMC Matters So Much in Cell and Gene Therapy?
Because it’s the point where science meets manufacturability—the place where a promising idea becomes something that can actually be delivered to patients.
Strong CMC isn’t just a regulatory requirement; it’s what ensures consistency, comparability, and true scalability from the very beginning.
At the Advanced Therapies Congress, we recorded an open, candid conversation between Dr. Robert Tressler, Chief Scientific Officer at Excellos, and James Adams, Chief Technology Officer at Tr1X. The discussion focused on how CMC is evolving—and why it has become the engine driving next-generation cell therapies forward.
They walked through the importance of deep process understanding, data-driven cell characterization, and integrated donor-to-dose strategies, and how these elements help programs move faster, more confidently, and with stronger manufacturing readiness as they approach the clinic.
If you missed it live, watch the full conversation below. It’s a thoughtful look at how science, technology, and manufacturing are converging to shape the future of cell therapy.
Watch now to gain practical insights from the CDMO trenches—and stay tuned for future sessions unpacking the latest advances shaping the future of cell and gene therapy.
Contact us to continue the conversation and explore how Excellos can support your program.
